BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 34854471)

  • 21. CRISPR mediated targeting of DUX4 distal regulatory element represses DUX4 target genes dysregulated in Facioscapulohumeral muscular dystrophy.
    Das S; Chadwick BP
    Sci Rep; 2021 Jun; 11(1):12598. PubMed ID: 34131248
    [TBL] [Abstract][Full Text] [Related]  

  • 22. MRI-informed muscle biopsies correlate MRI with pathology and DUX4 target gene expression in FSHD.
    Wang LH; Friedman SD; Shaw D; Snider L; Wong CJ; Budech CB; Poliachik SL; Gove NE; Lewis LM; Campbell AE; Lemmers RJFL; Maarel SM; Tapscott SJ; Tawil RN
    Hum Mol Genet; 2019 Feb; 28(3):476-486. PubMed ID: 30312408
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Quantitative proteomics reveals key roles for post-transcriptional gene regulation in the molecular pathology of facioscapulohumeral muscular dystrophy.
    Jagannathan S; Ogata Y; Gafken PR; Tapscott SJ; Bradley RK
    Elife; 2019 Jan; 8():. PubMed ID: 30644821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Nuclear bodies reorganize during myogenesis in vitro and are differentially disrupted by expression of FSHD-associated DUX4.
    Homma S; Beermann ML; Yu B; Boyce FM; Miller JB
    Skelet Muscle; 2016 Dec; 6(1):42. PubMed ID: 27906075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Deciphering transcription dysregulation in FSH muscular dystrophy.
    Ehrlich M; Lacey M
    J Hum Genet; 2012 Aug; 57(8):477-84. PubMed ID: 22718021
    [TBL] [Abstract][Full Text] [Related]  

  • 26. DUX4-induced dsRNA and MYC mRNA stabilization activate apoptotic pathways in human cell models of facioscapulohumeral dystrophy.
    Shadle SC; Zhong JW; Campbell AE; Conerly ML; Jagannathan S; Wong CJ; Morello TD; van der Maarel SM; Tapscott SJ
    PLoS Genet; 2017 Mar; 13(3):e1006658. PubMed ID: 28273136
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinically Advanced p38 Inhibitors Suppress DUX4 Expression in Cellular and Animal Models of Facioscapulohumeral Muscular Dystrophy.
    Oliva J; Galasinski S; Richey A; Campbell AE; Meyers MJ; Modi N; Zhong JW; Tawil R; Tapscott SJ; Sverdrup FM
    J Pharmacol Exp Ther; 2019 Aug; 370(2):219-230. PubMed ID: 31189728
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Expression of the human FSHD-linked DUX4 gene induces neurogenesis during differentiation of murine embryonic stem cells.
    Dandapat A; Hartweck LM; Bosnakovski D; Kyba M
    Stem Cells Dev; 2013 Sep; 22(17):2440-8. PubMed ID: 23560660
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Dnmt3b regulates DUX4 expression in a tissue-dependent manner in transgenic D4Z4 mice.
    Bouwman LF; den Hamer B; Verveer EP; Lerink LJS; Krom YD; van der Maarel SM; de Greef JC
    Skelet Muscle; 2020 Oct; 10(1):27. PubMed ID: 33004076
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Human miRNA miR-675 inhibits DUX4 expression and may be exploited as a potential treatment for Facioscapulohumeral muscular dystrophy.
    Saad NY; Al-Kharsan M; Garwick-Coppens SE; Chermahini GA; Harper MA; Palo A; Boudreau RL; Harper SQ
    Nat Commun; 2021 Dec; 12(1):7128. PubMed ID: 34880230
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Single-cell RNA sequencing in facioscapulohumeral muscular dystrophy disease etiology and development.
    van den Heuvel A; Mahfouz A; Kloet SL; Balog J; van Engelen BGM; Tawil R; Tapscott SJ; van der Maarel SM
    Hum Mol Genet; 2019 Apr; 28(7):1064-1075. PubMed ID: 30445587
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Multiple protein domains contribute to nuclear import and cell toxicity of DUX4, a candidate pathogenic protein for facioscapulohumeral muscular dystrophy.
    Corona ED; Jacquelin D; Gatica L; Rosa AL
    PLoS One; 2013; 8(10):e75614. PubMed ID: 24116060
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Direct interplay between two candidate genes in FSHD muscular dystrophy.
    Ferri G; Huichalaf CH; Caccia R; Gabellini D
    Hum Mol Genet; 2015 Mar; 24(5):1256-66. PubMed ID: 25326393
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Systemic antisense therapeutics inhibiting DUX4 expression ameliorates FSHD-like pathology in an FSHD mouse model.
    Lu-Nguyen N; Malerba A; Herath S; Dickson G; Popplewell L
    Hum Mol Genet; 2021 Jul; 30(15):1398-1412. PubMed ID: 33987655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Knocking Down DUX4 in Immortalized Facioscapulohumeral Muscular Dystrophy Patient-Derived Muscle Cells.
    Lim KRQ; Yokota T
    Methods Mol Biol; 2023; 2587():197-208. PubMed ID: 36401032
    [TBL] [Abstract][Full Text] [Related]  

  • 36. DUX4 activates germline genes, retroelements, and immune mediators: implications for facioscapulohumeral dystrophy.
    Geng LN; Yao Z; Snider L; Fong AP; Cech JN; Young JM; van der Maarel SM; Ruzzo WL; Gentleman RC; Tawil R; Tapscott SJ
    Dev Cell; 2012 Jan; 22(1):38-51. PubMed ID: 22209328
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Longitudinal measures of RNA expression and disease activity in FSHD muscle biopsies.
    Wong CJ; Wang LH; Friedman SD; Shaw D; Campbell AE; Budech CB; Lewis LM; Lemmers RJFL; Statland JM; van der Maarel SM; Tawil RN; Tapscott SJ
    Hum Mol Genet; 2020 Apr; 29(6):1030-1043. PubMed ID: 32083293
    [TBL] [Abstract][Full Text] [Related]  

  • 38. DUX4 expressing immortalized FSHD lymphoblastoid cells express genes elevated in FSHD muscle biopsies, correlating with the early stages of inflammation.
    Banerji CRS; Panamarova M; Zammit PS
    Hum Mol Genet; 2020 Aug; 29(14):2285-2299. PubMed ID: 32242220
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Induction of a local muscular dystrophy using electroporation in vivo: an easy tool for screening therapeutics.
    Derenne A; Tassin A; Nguyen TH; De Roeck E; Jenart V; Ansseau E; Belayew A; Coppée F; Declèves AE; Legrand A
    Sci Rep; 2020 Jul; 10(1):11301. PubMed ID: 32647247
    [TBL] [Abstract][Full Text] [Related]  

  • 40. DUX4-induced constitutive DNA damage and oxidative stress contribute to aberrant differentiation of myoblasts from FSHD patients.
    Dmitriev P; Bou Saada Y; Dib C; Ansseau E; Barat A; Hamade A; Dessen P; Robert T; Lazar V; Louzada RAN; Dupuy C; Zakharova V; Carnac G; Lipinski M; Vassetzky YS
    Free Radic Biol Med; 2016 Oct; 99():244-258. PubMed ID: 27519269
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.